Please assess the completion status of the following clinical trial:

Trial Title: AMD 3100 for Treatment of Myelokathexis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age over 18 years, WBC (white blood count) less than 3.0 x 10\^9 per Liter,~* Absolute neutrophil count less than 2.0 x 10\^9 per Liter,~* platelets greater than 100 x 10\^6 per Liter, creatinine less than 2.0/milligrams per/deciliter,~* Creatinine clearance \> 60 ml/min calculated,~* Aspartate Aminotransferase-GOT (SGOT), Alanin Aminotransferase-GPT (SGPT), bilirubin \< 2.5 upper limit of normal,~* Eastern Cooperative Oncology Group (ECOG) status 0 or 1,~* mutation identified and confirmed in CXCR4,~* on no granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage-colony stimulating factor (GM-CSF) within 3 weeks of the study drug~* patient signs consent, accepts contraception~Exclusion Criteria:~* greater than 18 years of age,~* sensitivity to plerixafor,~* pregnant,~* prisoner,~* decisionally impaired,~* judged unlikely to comply,~* illness that may interfere with interpretation of results,~* leukemia,~* malignancy,~* active infection requiring antibiotics within one week of study drug administration,~* history of cardiac conduction or electrocardiogram (EKG) abnormality,~* previous experimental therapy within one week.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMD3100 or plerixafor (Type: EXPERIMENTAL): SINGLE arm study with increasing doses of Plerixafor

Based on this trial design, predict the completion outcome and termination type (if applicable).